Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial
posted on 2021-03-26, 06:10authored byKeith M Godfrey, Sheila J Barton, Sarah El-Heis, Timothy Kenealy, Heidi Nield, Philip N Baker, Yap Seng Chong, Wayne Cutfield, Shiao-Yng Chan, NiPPeR Study Group
<b>Objective:</b> Better
preconception metabolic and nutritional health are hypothesized to promote
gestational normoglycemia and reduce preterm birth, but evidence supporting
improved outcomes with nutritional supplementation starting preconception is
limited.
<p><b>Research Design
and Methods:</b> Double-blind randomized controlled
trial recruited from the community 1729 UK, Singapore and New Zealand women
aged 18-38 years planning conception. We investigated if a nutritional
formulation containing
myo-inositol, probiotics and multiple micronutrients (intervention), compared
with a standard micronutrient supplement (control), taken preconception and
throughout pregnancy, could improve pregnancy outcomes. The primary
outcome was combined fasting, 1-hour and 2-hour post-load glycemia (28 weeks’
gestation oral
glucose tolerance test).</p>
<p><b>Results</b>: Between
2015-2017, participants were randomized to control (n=859) or intervention
(n=870); 585 conceived within 1-year and completed the primary outcome (295
intervention, 290 control). In an intention-to-treat analysis adjusting for site, ethnicity and preconception glycemia
with pre-specified p<0.017 for multiplicity, there were no differences in
gestational fasting, 1-hour and 2-hour glycemia between groups (β [95%CI] log<sub>e</sub> mmol/L intervention versus control: -0·004 [-0·018, 0·011], 0·025 [-0·014, 0·064],
0·040 [0·004, 0·077], respectively). Between the intervention
and control groups there were no
significant differences in gestational diabetes (24·8% versus 22·6%, adjusted risk ratio aRR=1·22 [0·92, 1·62]), birthweight (adjusted β=0·05kg [-0·03, 0·13]), or gestational age at birth (mean 39.3 versus
39.2 weeks, adjusted β=0·20 [-0·06,
0·46]), but there were fewer preterm births (5·8% versus 9·2%, aRR=0·43 [0·22, 0·82]) adjusting for pre-specified
covariates.</p>
<p><b>Conclusions: </b>Supplementation with
myo-inositol, probiotics and micronutrients preconception and in pregnancy did
not lower gestational glycemia, but did reduce preterm birth. </p>
<br>
Funding
Public good funding for this investigator-led study is through the UK Medical Research Council (as part of an MRC award to the MRC Lifecourse Epidemiology Unit (MC_UU_12011/4)); the Singapore National Research Foundation, National Medical Research Council (NMRC, NMRC/TCR/012-NUHS/2014); the National University of Singapore (NUS) and the Agency of Science, Technology and Research (as part of the Growth, Development and Metabolism Programme of the Singapore Institute for Clinical Sciences (SICS) (H17/01/a0/005); and as part of Gravida, a New Zealand Government Centre of Research Excellence. Funding for provision of the intervention and control drinks and to cover aspects of the fieldwork for the study has been provided by Société Des Produits Nestlé S.A under a Research Agreement with the University of Southampton, Auckland UniServices Ltd, SICS, National University Hospital Singapore PTE Ltd and NUS. KMG is supported by the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-10042), NIHR Southampton 1000DaysPlus Global Nutrition Research Group (17/63/154) and NIHR Southampton Biomedical Research Center (IS-BRC-1215-20004)), British Heart Foundation (RG/15/17/3174) and the European Union (Erasmus+ Programme Early Nutrition eAcademy Southeast Asia-573651-EPP-1-2016-1-DE-EPPKA2-CBHE-JP and ImpENSA 598488-EPP-1-2018-1-DE-EPPKA2-CBHE-JP). SYC is supported by a Singapore NMRC Clinician Scientist Award (NMRC/CSA-INV/0010/2016). The funders had no role in the data collection and analysis, and the decision to submit for publication.